Laura Clague
CIK 1388773 · Chief Financial Officer · last filed 2023-06-16
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
TVTX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
ESCONDIDO, CA 92025
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LAB | Director | 104,791 | $0.60 | $62.9K | $0 | 2 | 2023-06-16 |
| TVTX | Chief Financial Officer | 35,655 | $49.97 | $1.78M | -$972.2K | 12 | 2022-05-12 |
| GNSS | Director | 286,311 | $1.50 | $429.5K | -$83.5K | 6 | 2022-04-27 |
| STANDARD BIOTOOLS INC. (FLDM) Delisted | Director | 47,501 | $3.71 | $176.2K | $0 | 5 | 2021-05-27 |
| Travere Therapeutics, Inc. (RTRX) Delisted | Chief Financial Officer | 19,473 | — | — | -$955.7K | 21 | 2020-11-17 |
| Genasys Inc. (LRAD) Delisted | Director | 97,600 | — | — | -$14.5K | 11 | 2019-03-20 |
| Genasys Inc. (ATCO) Delisted | Director | 1,000 | $15.48 | $15.5K | $870 | 3 | 2008-12-15 |
Recent Filings · Page 6 of 6
60 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2016-05-23 | Travere Therapeutics, Inc. (RTRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-07-06 | Travere Therapeutics, Inc. (RTRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-03-19 | Genasys Inc. (LRAD) Delisted | Grant (A) | — | $0 | EDGAR |
| 2014-11-17 | Travere Therapeutics, Inc. (RTRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2014-03-28 | Genasys Inc. (LRAD) Delisted | Grant (A) | — | $0 | EDGAR |
| 2013-09-06 | Genasys Inc. (LRAD) Delisted | Mixed | +20,600 | -$76 | EDGAR |
| 2012-05-10 | Genasys Inc. (LRAD) Delisted | Grant (A) | — | $0 | EDGAR |
| 2008-12-15 | Genasys Inc. (ATCO) Delisted | Buy (P) | +2,000 | $870 | EDGAR |
| 2008-12-10 | Genasys Inc. (ATCO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2007-02-02 | Genasys Inc. (ATCO) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.